AVIR
Atea Pharmaceuticals, Inc.
$4.36
+0.93%
$345.7M
No data for this timeframe.
Vol
Market Cap$345.7M
Cap SizeSmall Cap
Inst. Holders8 funds
Inst. Value$61.8M
Inst. Activity4 buys / 1 sells
Insider Activity2B / 0S
Insider Net $$50.9K
SEC Reports3
Press Releases1
Recent Activity
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Bemnifosbuvir-Ruzasvir (BEM/RZR) (Phase 3)
Trial: C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Sponsor: At
May 18, 2026
Insider
Murphy Polly A. bought 6,100 shares
Director @ $4.17 ($25.4K)
May 12, 2026
SEC
Atea Pharmaceuticals reported Q1 2026 EPS of -$0.57, a 2.7% miss vs consensus of -$0.56, with net loss widening to $45.4
PRESS-RELEASE — Impact 5/10
Apr 27, 2026
SEC
Atea Pharmaceuticals filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting, scheduled for Ju
DEFA14A — Impact 2/10
Mar 11, 2026
Insider
Corcoran Andrea sold 60,000 shares
See Remarks @ $1.24 ($74.4K)
Mar 11, 2026
Insider
Corcoran Andrea sold 60,000 shares
See Remarks @ $0.00 ($0.00)
Mar 5, 2026
SEC
Atea Pharmaceuticals reported financial results for Q4 and full year 2025, highlighting continued advancement of its Pha
8-K — Impact 5/10
Inst.
FMR LLC — ADD
9,678,996 shares ($34.6M)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$8.67 (Mar 2026)
Current $4.36
Low $6.00
Median $10.00
High $10.00
3 analysts
$6.00
$10.00
Analyst Ratings
3Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 9, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.56 ▲ +1.8% | $-0.56 — $-0.55 | -26% YoY | 2 |
| Next Q | $-0.55 ▲ +0.9% | $-0.58 — $-0.51 | -3% YoY | 2 |
| Current FY | $-1.93 | $-2.20 — $-1.65 | 1% YoY | 2 |
| Next FY | $-1.39 | $-1.65 — $-1.12 | 28% YoY | 2 |
Latest Reports
BEARISH
PRESS-RELEASE
5/10
Atea Pharmaceuticals reported Q1 2026 EPS of -$0.57, a 2.7% miss vs consensus of -$0.56, with net loss widening to $45.4
May 12, 2026
NEUTRAL
DEFA14A
2/10
Atea Pharmaceuticals filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting, scheduled for Ju
Apr 27, 2026
MIXED
Press
6/10
Atea Pharmaceuticals reported financial results for Q4 and full year 2025, showing increased R&D spend due to its Phase
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $34.6M | ADD |
| VANGUARD GROUP INC | $15.1M | — |
| RENAISSANCE TECHNOLOGIES LLC | $4.2M | — |
| TWO SIGMA INVESTMENTS, LP | $2.7M | ADD |
| MORGAN STANLEY | $2.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Murphy Polly | BUY | $25.4K |
| Mar 11, 2026 | Corcoran Andrea | M | $74.4K |
| Mar 11, 2026 | Corcoran Andrea | M | $0.00 |
| Feb 3, 2026 | Sommadossi Jean-Pierre | M | $372.0K |
| Feb 3, 2026 | Sommadossi Jean-Pierre | M | $0.00 |
8 institutional holders with $61.8M total value (17,319,476 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, RENAISSANCE. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 9,678,996 | $34.6M | 55.9% | ADD +66.2% |
| 2 | VANGUARD GROUP INC | 4,227,110 | $15.1M | 24.4% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 1,188,500 | $4.2M | 6.9% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 745,415 | $2.7M | 4.3% | ADD +58.2% |
| 5 | MORGAN STANLEY | 656,075 | $2.3M | 3.8% | ADD +45.6% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 607,792 | $2.2M | 3.5% | NEW |
| 7 | BANK OF AMERICA CORP /DE/ | 135,794 | $484.8K | 0.8% | TRIM -56.7% |
| 8 | WELLS FARGO & COMPANY/MN | 79,794 | $284.9K | 0.5% | ADD +35.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 5,822,773 | 9,678,996 | +66.2% | $34.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 471,293 | 745,415 | +58.2% | $2.7M | 2025-Q4 |
| MORGAN STANLEY | ADD | 450,564 | 656,075 | +45.6% | $2.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 313,644 | 135,794 | -56.7% | $484.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 58,873 | 79,794 | +35.5% | $284.9K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 366,612 | 471,293 | +28.6% | $1.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 109,739 | 313,644 | +185.8% | $909.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 251,749 | 366,612 | +45.6% | $1.3M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 60,661 | 109,739 | +80.9% | $395.1K | 2025-Q2 |
| UBS Group AG | ADD | 63,568 | 109,424 | +72.1% | $393.9K | 2025-Q2 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 231,088 | 25,792 | -88.8% | $77.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 625,149 | 231,088 | -63.0% | $774.1K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 35,526 | 45,391 | +27.8% | $152.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 650,157 | — | $2.2M | 2024-Q3 |
| MORGAN STANLEY | ADD | 367,540 | 488,899 | +33.0% | $1.6M | 2024-Q3 |
7 unique insiders with 2 transactions. Net insider value: $50.9K ($50.9K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Murphy Polly A. | Director | BUY | 6,100 | $4.17 | $25.4K |
| Mar 11, 2026 | Corcoran Andrea | See Remarks | M | 60,000 | $1.24 | $74.4K |
| Mar 11, 2026 | Corcoran Andrea | See Remarks | M | 60,000 | $0.00 | $0.00 |
| Feb 3, 2026 | Sommadossi Jean-Pierre | President, CEO, and Chairman | M | 300,000 | $1.24 | $372.0K |
| Feb 3, 2026 | Sommadossi Jean-Pierre | President, CEO, and Chairman | M | 300,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Corcoran Andrea | See Remarks | M | 54,866 | $0.00 | $0.00 |
| Jan 31, 2026 | Corcoran Andrea | See Remarks | F | 16,104 | $4.24 | $68.3K |
| Jan 31, 2026 | Corcoran Andrea | See Remarks | M | 44,366 | $0.00 | $0.00 |
| Jan 31, 2026 | Corcoran Andrea | See Remarks | A | 180,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Sommadossi Jean-Pierre | President, CEO, and Chairman | M | 272,983 | $0.00 | $0.00 |
| Jan 31, 2026 | Sommadossi Jean-Pierre | President, CEO, and Chairman | F | 106,093 | $4.24 | $449.8K |
| Jan 31, 2026 | Sommadossi Jean-Pierre | President, CEO, and Chairman | M | 173,466 | $0.00 | $0.00 |
| Jan 31, 2026 | Horga Maria Arantxa | Chief Medical Officer | M | 51,283 | $0.00 | $0.00 |
| Jan 31, 2026 | Horga Maria Arantxa | Chief Medical Officer | F | 16,073 | $4.24 | $68.1K |
| Jan 31, 2026 | Horga Maria Arantxa | Chief Medical Officer | M | 41,533 | $0.00 | $0.00 |
| Jan 31, 2026 | Horga Maria Arantxa | Chief Medical Officer | A | 173,500 | $0.00 | $0.00 |
| Jan 31, 2026 | Vavricka John | Chief Commercial Officer | M | 42,083 | $0.00 | $0.00 |
| Jan 31, 2026 | Vavricka John | Chief Commercial Officer | F | 11,570 | $4.24 | $49.1K |
| Jan 31, 2026 | Vavricka John | Chief Commercial Officer | M | 33,333 | $0.00 | $0.00 |
| Jan 31, 2026 | Vavricka John | Chief Commercial Officer | A | 119,520 | $0.00 | $0.00 |
| Jan 31, 2026 | Hammond Janet MJ | Chief Development Officer | M | 58,050 | $0.00 | $0.00 |
| Jan 31, 2026 | Hammond Janet MJ | Chief Development Officer | F | 14,136 | $4.24 | $59.9K |
| Jan 31, 2026 | Hammond Janet MJ | Chief Development Officer | M | 46,800 | $0.00 | $0.00 |
| Jan 31, 2026 | Hammond Janet MJ | Chief Development Officer | A | 177,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Foster Wayne | EVP, Chief Accounting Officer | M | 41,333 | $0.00 | $0.00 |
| Jan 31, 2026 | Foster Wayne | EVP, Chief Accounting Officer | F | 12,132 | $4.24 | $51.4K |
| Jan 31, 2026 | Foster Wayne | EVP, Chief Accounting Officer | M | 33,333 | $0.00 | $0.00 |
| Jan 31, 2026 | Foster Wayne | EVP, Chief Accounting Officer | A | 108,000 | $0.00 | $0.00 |
| May 18, 2025 | Murphy Polly A. | Director | BUY | 6,100 | $4.17 | $25.4K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
BEARISH
PRESS-RELEASE
5/10
Atea Pharmaceuticals reported Q1 2026 EPS of -$0.57, a 2.7% miss vs consensus of -$0.56, with net lo
May 12, 2026
NEUTRAL
DEFA14A
2/10
Atea Pharmaceuticals filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeti
Apr 27, 2026
NEUTRAL
8-K
5/10
Atea Pharmaceuticals reported financial results for Q4 and full year 2025, highlighting continued ad
Mar 5, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 78% buy across 9 analysts — 3 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$8.67 mean target (Mar 2026)
$6.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $4.36 |
| Target Low | $6.00 |
| Target Mean | $8.67 |
| Target Median | $10.00 |
| Target High | $10.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.56 | $-0.56 | $-0.55 | -26.1% | +1.8% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.55 | $-0.58 | $-0.51 | -2.8% | +0.9% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.93 | $-2.20 | $-1.65 | 0.8% | +0.3% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.39 | $-1.65 | $-1.12 | 28.1% | +0.0% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.555 | |
| 7d ago | $-0.565 | +0.010 |
| 30d ago | $-0.565 | +0.010 |
| 60d ago | $-0.565 | +0.010 |
| 90d ago | $-0.520 | -0.035 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 9, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Jan 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
Clinical Trial
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Bemnifosbuvir-Ruzasvir (BEM/RZR) (Phase 3)
Trial: C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Sponsor: Atea Pharmaceuticals, Inc.
Phase: Phase 3 | Status:
May 27, 2026
other
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting A
May 13, 2026
earnings_calendar
AVIR Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mi
May 12, 2026
earnings_calendar
AVIR Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
AVIR Q1 2026 Earnings Scheduled — 2026-05-11
Mar 5, 2026
earnings
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American </em><
Mar 5, 2026
earnings_calendar
AVIR Q4 2025 Earnings After Market Close — 2026-03-05
Mar 3, 2026
earnings_calendar
AVIR Q4 2025 Earnings After Market Close — 2026-03-03